Sign in

MRKR on Nasdaq

Marker Therapeutics, Inc.

In its 2026 annual report the company says: “We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.”4 It is headquartered in Houston, Texas.1 Its shares trade on Nasdaq under the symbol MRKR.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Camp4 Therapeutics Corp, Radiopharm Theranostics Ltd or Kala Pharmaceuticals (United States), or pick any stock.

  • TickerMRKR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHouston, Texas1
  • Incorporated inDE2
  • Business address2450 Holcombe Blvd, Tmc Partners Office 1.311, Houston, Tx 770212
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker’s Multi Antigen Recognizing (“MAR”)-T cell technology is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. This approach selectively expands natural tumor-specific T cells from a patient’s/donor’s blood that are capable of recognizing a broad range of tumor associated antigens, or TAAs. Unlike other T cell therapies, MAR-T cells are able to recognize hundreds of different epitopes within up to six tumor-specific antigens to produce broad spectrum anti-tumor activity. Targeting multiple antigens simultaneously exploits the natural capacity of T cells to recognize and kill tumor target…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-363.5%Operating margin5
-343.0%Net margin5
-46.2%Revenue growth, 20255
-72.4%Return on equity5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia brought in 25% of the revenue Marker Therapeutics, Inc. broke down this way in fiscal 2025.

  1. Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia$900.0K525%down 80% from 2024
  2. National Institutes of Health Small Business Innovation Research For Lymphoma Grant$665.0K519%up 0% from 2024
  3. CPRIT Pancreatic Grant$574.0K516%
  4. National Institutes of Health Small Business Innovation Research$472.2K513%down 52% from 2024
  5. National Institutes of Health Small Business Innovation Research For Pancreatic Cancer$425.7K512%up 5831% from 2024
  6. National Institutes of Health National Cancer Institute Grant$391.3K511%up 6621% from 2024
  7. FDA Grant$118.5K53%down 77% from 2024
Products and services by year
Products and services20242025
Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia$4.4M$900.0K
National Institutes of Health Small Business Innovation Research For Lymphoma Grant$665.0K$665.0K
CPRIT Pancreatic Grant$574.0K
National Institutes of Health Small Business Innovation Research$982.2K$472.2K
National Institutes of Health Small Business Innovation Research For Pancreatic Cancer$7.2K$425.7K
National Institutes of Health National Cancer Institute Grant$5.8K$391.3K
FDA Grant$519.8K$118.5K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$11.8M
  • Income tax0¢$15.2K

Out of $3.5M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$3.5M in 2025+1564% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $213.2K$213.2K20192020: $500.0K$500.0K2020+135%2021: $0$020212022: $3.5M$3.5M20222023: $3.3M$3.3M2023−6%2024: $6.6M$6.6M2024+99%2025: $3.5M$3.5M2025−46%
Operating income10711895-$12.9M in 2025−43% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$22.5M-$22.5M20192020: -$28.9M-$28.9M2020+28%2021: -$39.5M-$39.5M2021+37%2022: -$19.8M-$19.8M2022−50%2023: -$14.6M-$14.6M2023−26%2024: -$11.1M-$11.1M2024−24%2025: -$12.9M-$12.9M2025+16%
Net income10711895-$12.2M in 2025−43% since 2019
-$60.0M-$40.0M-$20.0M02019: -$21.4M-$21.4M20192020: -$28.7M-$28.7M2020+34%2021: -$41.9M-$41.9M2021+46%2022: -$29.9M-$29.9M2022−29%2023: -$8.2M-$8.2M2023−72%2024: -$10.7M-$10.7M2024+30%2025: -$12.2M-$12.2M2025+13%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Total revenues$3.5M$6.6M
Research and development$11.8M$13.5M
General and administrative$4.2M$4.2M
Loss on early termination of vendor agreement$453.1K
Total operating expenses$16.4M$17.7M
Loss from operations-$12.9M-$11.1M
Interest income$594.2K$437.0K
Other income$117.4K
Loss from operations before income taxes-$12.2M-$10.7M
Income tax (benefit) expense-$15.2K$50.0K
Net loss-$12.2M-$10.7M
Net loss per share, basic (in dollars per share)-$0.79-$1.19
Net loss per share, diluted (in dollars per share)-$0.79-$1.19
Basic (in shares)15.3M shares9.0M shares
Diluted (in shares)15.3M shares9.0M shares

Compare Marker Therapeutics, Inc. with another company

Corporate structure

Marker Therapeutics, Inc. sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Marker Therapeutics, Inc.

  • New Enterprise Associates 16, L.P. Filed SCHEDULE 13D/A on Marker Therapeutics, Inc., latest Nov 17, 2025 (4 filings since May 17, 2024)
  • Alyeska Investment Group, L.P. Filed SCHEDULE 13G/A on Marker Therapeutics, Inc., latest Nov 14, 2025 (2 filings since Feb 14, 2025)
  • John Robert Wilson Filed SCHEDULE 13D/A on Marker Therapeutics, Inc., latest Aug 20, 2025 (2 filings since Aug 19, 2025)
  • Blue Owl Capital Filed SCHEDULE 13G/A on Marker Therapeutics, Inc., latest May 15, 2025 (2 filings since Feb 14, 2025)
  • Aisling Capital IV, LP Filed SC 13D/A on Marker Therapeutics, Inc., latest Mar 3, 2023
  • Marker Therapeutics, Inc. Houston, Texas
    • GeneMax Pharmaceuticals Subsidiary · Canada

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Marker Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$16.1M5 Dec 31, 2025$19.2M5 Dec 31, 2024−16.3%

Properties, in its own words

We do not own any real estate or other properties. We utilize office space at 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, TX 77021, which is also our principal business office.

Item 2 of the 10-K filed Mar 18, 2026.4

Leadership

Who has led Marker Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Denis Corin2007–2009
  2. Glynn Wilson2011–2017
  3. Peter L. Hoang2017–2022
  4. Juan Vera2023–now

Chair

  1. Glynn Wilson2009–2011

President

  1. Denis Corin2007–2012
  2. John N. Bonfiglio2016–2017
  3. Peter L. Hoang2017–2022
  4. Juan Vera2023–now

Chief financial officer

  1. Patrick A. McGowan2007
  2. Tracy A. Moore2009
  3. Denis Corin2011
  4. Michael Loiacono2016–2018
  5. Anthony H. Kim2018–2022
  6. Eliot M. Lurier2023

Chief operating officer

  1. John N. Bonfiglio2016–2017
  2. Juan Vera2022–2023
2010201520202025
Board members and other officers (29)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJohn Wilson named Dec 30, 202453

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • GeneMax Pharmaceuticals Canada, Inc.3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • TAPIMMUNE INC.Jul 11, 2017 to Oct 17, 20182
  • TAPIMMUNE INCJul 3, 2007 to Jun 29, 20172
  • GENEMAX CORPJul 18, 2002 to Jun 28, 20072
  • EDUVERSE COMSep 29, 1999 to Jun 17, 20022

Timeline

  1. May 4, 20268-K Bylaws or fiscal year changed; Shareholder vote54
  2. Mar 19, 20268-K Results of operations55
  3. Feb 9, 20268-K Director nominations56
  4. Nov 14, 20258-K Results of operations57
  5. Nov 5, 20258-K Executive or director change; Other events58
  6. Oct 6, 20258-K Other events59
  7. Aug 26, 20258-K Regulation FD disclosure60
  8. Aug 12, 20258-K Change of auditor61
  9. Jun 17, 20258-K Entered a material agreement; Other events62
  10. Jun 9, 20258-K Shareholder vote63
  11. May 20, 20258-K Other events64
  12. Mar 31, 20258-K Results of operations65
  13. May 11, 2023New chief executive Juan Vera becomes CEO14
  14. Sep 25, 2017New chief executive Peter L. Hoang becomes CEO15
  15. Apr 5, 2011New chief executive Glynn Wilson becomes CEO16
  16. Jul 3, 2007New chief executive Denis Corin becomes CEO17

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.12) a share, on Nov 13, 2025.66

When it reported results

  1. Mar 19, 2026Reported quarterly or annual results55
  2. Nov 14, 2025Reported quarterly or annual results57
  3. Mar 31, 2025Reported quarterly or annual results65
  4. Nov 14, 2024Reported quarterly or annual results67
  5. Aug 14, 2024Reported quarterly or annual results68
  6. May 15, 2024Reported quarterly or annual results69
  7. Mar 26, 2024Reported quarterly or annual results70
  8. Nov 9, 2023Reported quarterly or annual results71

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

177 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 67 major events, 43 insider forms, 11 large holders, 1 private raises, 35 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. May 15, 202610-Q EDGAR
  3. May 4, 20268-K EDGAR
  4. Mar 20, 2026DEFA14A EDGAR
  5. Mar 20, 2026ARS EDGAR
  6. Mar 20, 2026DEF 14A EDGAR
  7. Mar 19, 20268-K EDGAR
  8. Mar 18, 202610-K EDGAR
  9. Mar 10, 2026PRE 14A EDGAR
  10. Feb 9, 20268-K EDGAR
  11. Nov 19, 20254 PRIMARY DOCUMENT EDGAR
  12. Nov 19, 20254 PRIMARY DOCUMENT EDGAR
  13. Nov 19, 20254 OWNERSHIP DOCUMENT EDGAR
  14. Nov 17, 2025SCHEDULE 13D/A EDGAR
  15. Nov 14, 2025SCHEDULE 13G/A EDGAR
  16. Nov 14, 20258-K EDGAR
  17. Nov 13, 202510-Q EDGAR
  18. Nov 5, 20258-K EDGAR
  19. Nov 4, 20254 PRIMARY DOCUMENT EDGAR
  20. Nov 4, 20253 PRIMARY DOCUMENT EDGAR

The 177 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 23, 2024ELMS STEVEDirectorBuy11,085$3.20$35.5KForm 4
Dec 23, 2024NEA Partners 16, L.P.10% ownerBuy554,250$3.20$1.8MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025President and ChiefExecutive Officer $415.4K$741.2K77
2024President and ChiefExecutive Officer $400.0K77

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 23, 2024Raised $16.1 million in a private offering of equity Form D: 5 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 35. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
NEA Management Company, LLC1,625,678$2.4M0.2%No change
Blue Owl Capital Holdings LP554,250$814.7K0.1%No change
Vanguard Capital Management LLC426,169$626.5K0.0%+36,850
Aisling Capital Management LP325,370$478.3K0.1%No change
Renaissance Technologies LLC249,423$366.7K0.0%+74,129
Geode Capital Management, LLC139,816$205.6K0.0%−21,094
Osaic Holdings, Inc.112,649$165.6K0.0%+19,528
Vanguard Fiduciary Trust Co87,269$128.3K0.0%No change
LPL Financial LLC83,147$122.2K0.0%+100
Concurrent Investment Advisors, LLC67,963$99.9K0.0%New
Two Sigma Investments, LP60,201$88.5K0.0%−800
XTX Topco Ltd45,357$66.7K0.0%−18,210
Northern Trust Corp34,629$50.9K0.0%+8,620
Citadel Advisors LLC32,517$47.8K0.0%New
State Street Corp20,948$30.8K0.0%No change
Invst, LLC18,000$26.5K0.0%−11,000
Creative Planning17,312$25.4K0.0%No change
Jane Street Group, LLC16,832$24.7K0.0%−19,471
Ashton Thomas Private Wealth, LLC16,400$24.1K0.0%No change
Fifth Third Bancorp10,000$14.7K0.0%No change
UBS Group AG8,150$12.0K0.0%−24,219
Vanguard Global Advisers, LLC2,512$3.7K0.0%No change
International Assets Investment Management, LLC2,000$2.9K0.0%No change
Tower Research Capital LLC (TRC)810$1.2K0.0%−2,327
Wells Fargo & Company/mn232$3410.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Marker Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMarker Therapeutics, Inc.1
  • CIK0001094038
  • Employer ID (EIN)45-44979414
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2450 Holcombe Blvd, Tmc Partners Office 1.311, Houston, TX 770211
  • Phone(713) 400-64001
  • Shares outstanding16,673,127 as of Aug 7, 202613
  • Public float$17.3M as of Jun 30, 20254
  • AuditorMarcum LLP, Houston, TX PCAOB ID 688; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceSep 3, 19991
  • Filings903 in all: 8-K (205), 4 (154), 3 (57), 10-Q (56), CORRESP (32), NT 10-Q (29), UPLOAD (29), SC 13D (27)1
    All 65 form types

    10QSB (25), 5 (21), 10-K (18), SC 13D/A (17), 424B3 (15), NT 10-K (15), SC 13G/A (15), DEF 14A (13), EFFECT (13), SC 13G (11), 10-Q/A (9), D (9), 10KSB (8), 424B5 (8), DEFA14A (8), S-3 (8), REGDEX (7), S-8 (7), 8-K/A (6), PRE 14A (6), 10QSB/A (5), SCHEDULE 13D/A (5), 4/A (4), 424B7 (4), ARS (4), POS AM (4), 10KSB/A (3), CT ORDER (3), DEF 14C (3), PRE 14C (3), S-1 (3), S-3/A (3), 10-K/A (2), PRER14A (2), REGDEX/A (2), S-1/A (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), 10KSB40 (1), 10SB12G (1), 10SB12G/A (1), 3/A (1), 8-A12B (1), 8-A12B/A (1), CERTNAS (1), D/A (1), DEFM14A (1), DEFR14A (1), DEFS14A (1), DEL AM (1), NT 10-Q/A (1), NTN 10K (1), PREM14A (1), PRER14C (1), PRES14A (1), RW (1), S-8 POS (1)

  • Latest filingsAnnual report (10-K) Mar 18, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Mar 20, 2026
    Latest 8-K (8-K) May 4, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareMRKRNasdaq

From the cover page of the 10-K filed Mar 18, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Marker Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 18, 2026: 52 risks under these headings, as written.4

  • Risks Associated with Our Business
  • Risks Related to our Financial Position and Capital Needs
  • We are a clinical stage company with a history of operating losses, and we expect losses to continue for the indefinite future. These factors raise substantial doubt regarding our ability to continue as a going concern.
  • Risks Related to the Development of our Product Candidates
  • All of our product candidates are in clinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our product candidates, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed.
  • The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
  • Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates.
  • The results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.
  • If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed.
  • Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.
  • We may not obtain or maintain the benefits associated with orphan drug designation, including market exclusivity.
  • Risks Related to Manufacturing
The other 44 risks
  • We rely on third-party vendors and contract manufacturing organizations to maintain and support our manufacturing and cell processing operations.
  • Our manufacturing process is reliant upon specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. We, our vendors, and contract manufacturing organizations rely or may rely on sole-source vendors or a limited number of vendors, which could impair the manufacture and supply of our product candidates.
  • The manufacture of our product candidates is complex and we may encounter difficulties in production, particularly with respect to process development. If any of our third-party suppliers encounter such difficulties, the supply of our product candidates for clinical trials, or our product candidates for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.
  • No assurance can be given that we will be able to develop a new, FDA-compliant, more efficient, lower cost manufacturing process upon which our business plan to commercialize MAR-T cell-based product candidates is dependent.
  • Risks Related to our Reliance on Third Parties
  • We rely on third parties for the clinical and, if approved, commercial manufacture of our product candidates. The third-party manufacturing facilities on which we rely may have limited capacity or fail to meet the applicable stringent regulatory requirements.
  • Our strategic relationship with BCM is dependent, in part, upon our ongoing relationship with key medical and scientific personnel and advisors.
  • We may not be able to establish or maintain the third-party relationships, including strategic collaborations, that are necessary to develop, commercialize and/or market some or all of our product candidates.
  • Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Risks Related to the Commercialization of our Product Candidates
  • Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community.
  • Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
  • Our future success is highly dependent upon our key personnel, and our ability to attract, retain, and motivate additional qualified personnel. We will also be required to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any approved products.
  • The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.
  • The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.
  • New regulatory pathways for biosimilar competition could reduce the duration of market exclusivity for our products.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • Risks Related to Our Intellectual Property
  • If we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.
  • The use of our technologies could potentially conflict with the rights of others.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • If we fail to comply with any obligations under our existing license agreements or any future license agreements, or disputes arise with respect to those agreements, it could have a negative impact on our business and our intellectual property rights.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • Certain of our technologies are in-licensed from third parties, and the protection of those technologies is not entirely within our control.
  • We rely upon patents and licensed technologies to protect our technology. We may be unable to protect our intellectual property rights, and we may be liable for infringing the intellectual property rights of others.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensor, which could be expensive, time-consuming and unsuccessful.
  • We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
  • If we are unable to obtain licenses needed for the development of our product candidates, or if we breach any of the agreements under which we license rights to patents or other intellectual property from third parties, we could lose license rights that are important to our business.
  • Risks Related to Government Regulation
  • We are subject to extensive regulation, which can be costly, time consuming and can subject us to unanticipated delays. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.
  • Recently enacted and future legislation in the United States and other countries may affect the prices we may obtain for our product candidates and increase the difficulty and cost to commercialize our product candidates.
  • We are subject to stringent and changing laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.
  • Risks Related to our Securities
  • The price of our stock may be volatile.
  • Sales of additional equity securities may adversely affect the market price of our common stock and your rights may be reduced. Our stockholders may experience dilution in the future and it may adversely affect the market price of our securities.
  • We do not intend to pay cash dividends.
  • General Risk Factors
  • From time to time, we may become involved in legal proceedings.
  • If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, or are perceived to have been compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.
  • As a result of being a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.
  • Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to limitation.
  • Catastrophic events may disrupt our business.
  • Our business and operations could be adversely affected by the effects of health epidemics, including pandemics.
  • Unfavorable global political or economic conditions could adversely affect our business, financial condition or results of operations.
  • Changes in tax laws or regulations could materially adversely affect our company.

Legal proceedings

From time to time, we may become involved in legal proceedings, including those arising in the ordinary course of our business. We are not currently a party to any material legal proceedings that we believe could have an adverse effect on our business, operating results or financial condition.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
    SEC EDGAROther events
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
    SEC EDGAROther events
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77